(Reuters) - Supernus Pharmaceuticals Inc said the U.S. Food and Drug Administration granted a tentative approval to its generic epilepsy treatment Trokendi XR, sending its shares up as much as 164 percent. The company said the U.S. FDA completed a review of Trokendi, an extended release version of Johnson & Johnson's widely used epilepsy drug Topamax, and did not seek any additional clinical ...

Read the original article
Brought to you by Yahoo! News

Return to Epilepsy News